Ganetespib (STA-9090)

Name: Ganetespib (STA-9090)
Brand: Selleck Chemicals
SKU: S1159
Rating: 5 (40 reviews)

For research use only.

Catalog No.S1159

40 publications

Ganetespib (STA-9090) Chemical Structure

CAS No. 888216-25-9

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.

Selleck's Ganetespib (STA-9090) has been cited by 40 publications

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nature, 2017, 10.1038/nature21064

PubMed: 28178232 ( click the link to review the publication )

Cell, 2017, 168(5):856-866

PubMed: 28215707 ( click the link to review the publication )

Cell Death Dis, 2021, 12(1):126

PubMed: 33500390 ( click the link to review the publication )

Cell Chem Biol, 2021, S2451-9456(21)00221-X

PubMed: 34077750 ( click the link to review the publication )

Cancer Biol Med, 2021, j.issn.2095-3941.2020.0262

PubMed: 33764710 ( click the link to review the publication )

Sci China Life Sci, 2021, 10.1007/s11427-020-1860-2

PubMed: 33439458 ( click the link to review the publication )

Cancer Discov, 2020, 10(5):674-687

PubMed: 32213539 ( click the link to review the publication )

Onco Targets Ther, 2020, 13:2997-3011

PubMed: 32308431 ( click the link to review the publication )

Theranostics, 2020, 10(18):8415-8429

PubMed: 32724478 ( click the link to review the publication )

Nat Commun, 2019, 10(1):402

PubMed: 30679438 ( click the link to review the publication )

PLoS Biol, 2019, 17(3):e3000178

PubMed: 30865623 ( click the link to review the publication )

Theranostics, 2019, 9(2):554-572

PubMed: 30809293 ( click the link to review the publication )

Cell Death Dis, 2019, 10(12):911

PubMed: 31801945 ( click the link to review the publication )

Endocr Relat Cancer, 2019, 10.1530/ERC-18-0509

PubMed: 30730850 ( click the link to review the publication )

Food Chem Toxicol, 2019, 132:110645

PubMed: 31254591 ( click the link to review the publication )

Front Endocrinol (Lausanne), 2019, 10:487

PubMed: 31379752 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2019.220871

PubMed: 31439673 ( click the link to review the publication )

ACS Chem Neurosci, 2019, 10(6):2890-2902

PubMed: 31017387 ( click the link to review the publication )

Hepatology, 2019, 69(2):573-586

PubMed: 29356025 ( click the link to review the publication )

Transl Lung Cancer Res, 2019, 8(4):340-351

PubMed: 31555510 ( click the link to review the publication )

Mol Cell, 2018, 69(4):594-609

PubMed: 29452639 ( click the link to review the publication )
Autophagy, 2018, 14(6):958-971

PubMed: 29561705 ( click the link to review the publication )

Mol Syst Biol, 2018, 14(7):e8071

PubMed: 29997244 ( click the link to review the publication )

Mol Cancer Res, 2018, 10.1158/1541-7786

PubMed: 30002191 ( click the link to review the publication )

Oncotarget, 2018,

PubMed: 29599910 ( click the link to review the publication )

Oncotarget, 2018, 9(43-:27242-27255

PubMed: 29930762 ( click the link to review the publication )

Nat Commun, 2017, 8(1):422

PubMed: 28871086 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1779-1790

PubMed: 28619753 ( click the link to review the publication )

Sci Rep, 2017, 7(1):6420

PubMed: 28743892 ( click the link to review the publication )

Sci Rep, 2017, 7(1):1232

PubMed: 28450729 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2017, 329:282-292

PubMed: 28624441 ( click the link to review the publication )

Oncotarget, 2017, 8(25):41294-41304

PubMed: 28476040 ( click the link to review the publication )

Medicinal Chemistry Research, 2016, 10.1007/s00044-016-1553-7

PubMed: ( click the link to review the publication )

Hum Mol Genet, 2015, 10.1093/hmg/ddv136

PubMed: 25877301 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1017

PubMed: 25297628 ( click the link to review the publication )

Cell Death Dis, 2014, 6:e1595

PubMed: 25590805 ( click the link to review the publication )

Cancer Chemoth Pharm, 2014, 74(5):1015-22

PubMed: 25205430 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HSP (HSP90) Inhibitors

Biological Activity

Description

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.

Targets

HSP90 ^[1]
(OSA 8 cells)

4 nM

In vitro

The 50% inhibitory concentrations (IC50) for Ganetespib against malignant mast cell lines are 10-50 times lower than that for 17-AAG, indicating that triazolone class of HSP90 inhibitors likely exhibits greater potency than geldanamycin based inhibitors. ^[1] Ganetespib inhibits MG63 cell lines with IC50 of 43 nM. ^[1] Ganetespib binds to the ATP-binding domain at the N-terminus of Hsp90 and serves as a potent Hsp90 inhibitor by causing degradation of multiple oncogenic Hsp90 client proteins including HER2/neu, mutated EGFR, Akt, c-Kit, IGF-1R, PDGFRα, Jak1, Jak2, STAT3, STAT5, HIF-1α, CDC2 and c-Met as well as Wilms' tumor 1. ^[2] Ganetespib, at low nanomolar concentrations, potently arrests cell proliferation and induces apoptosis in a wide variety of human cancer cell lines, including many receptor tyrosine kinase inhibitor- and tanespimycin-resistant cell lines. Ganetespib exhibits potent cytotoxicity in a range of solid and hematologic tumor cell lines, including those that express mutated kinases that confer resistance to small-molecule tyrosine kinase inhibitors. ^[3] Ganetespib treatment rapidly caused the degradation of known Hsp90 client proteins, exhibits superior potency to the ansamycin inhibitor 17-AAG, and shows sustained activity even with short exposure times.^[3] In anohter study, Ganetespib induces apoptosis of malignant canine mast cell lines. Ganetespib is active at significantly lower concentrations for C2 and BR canine malignant mast cells with IC50 of 19 and 4 nM, respectively, while 17-AAG inhibits C2 and BR canine malignant mast cells with IC50 of 958 and 44 nM, respectively. ^[4] Both the expression of WT and mutant Kit are downregulated by 100 nM Ganetespib after 24 hours in all lines treated including C2 and BMCMCs cells. However, no effects on PI3K or HSP90 expression are observed following treatment with Ganetespib.^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
NCI-H1975	M2G2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVPnOm1oPzJiaB?=		NF[4VVVKSzVyPUigcm0>	M1PCbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUS0OlY2Lz5{MkG0OFY3PTxxYU6=
NCI-H1975	M1G1VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXq2bI5RPDhiaB?=		MkKzTWM2OD1zNjDuUS=>	MmrFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNES2OlUoRjJ{MUS0OlY2RC:jPh?=
Calu-6	NEfjeG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4rqVmlEPTB;NkSgcm0>	NWXsbmE{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwNVIzPDhpPkKzNFEzOjR6PD;hQi=>
Calu-1	NHHkUWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mlz0TWM2OD13ODDuUS=>	M4HkVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEGyNlQ5Lz5{M{CxNlI1QDxxYU6=
H2122	MoLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX7JR\|UxRTV\|IH7N	Mmr3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyMUKyOFgoRjJ\|MEGyNlQ5RC:jPh?=
A549	NHvCclNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1jaOGlEPTB;NEOgcm0>	M3OxOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEGyNlQ5Lz5{M{CxNlI1QDxxYU6=
H358	NVjRXpZmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4fuS2lEPTB;Mkmgcm0>	NG\DWIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{CxNlI1QCd-MkOwNVIzPDh:L3G+
H1734	NF\kVXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTJ6IH7N	M3fXXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEGyNlQ5Lz5{M{CxNlI1QDxxYU6=
H727	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4LXcWlEPTB;Mkigcm0>	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzBzMkK0PEc,OjNyMUKyOFg9N2F-
COR-L23	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWrjb3RXUUN3ME2yNkBvVQ>?	NWDQb4x7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwNVIzPDhpPkKzNFEzOjR6PD;hQi=>
H1792	MorGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH7tU3BKSzVyPUKwJI5O	MonPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyMUKyOFgoRjJ\|MEGyNlQ5RC:jPh?=
H2009	Ml\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUCwTG9QUUN3ME2xPUBvVQ>?	M4m0UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEGyNlQ5Lz5{M{CxNlI1QDxxYU6=
SK-LU-1	M3ryZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NILrZ5NKSzVyPUG4JI5O	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzBzMkK0PEc,OjNyMUKyOFg9N2F-
H2212	NIfpb5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEDnUXlKSzVyPUG3JI5O	Mm\4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyMUKyOFgoRjJ\|MEGyNlQ5RC:jPh?=
H441	NVvQUIpGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk\6TWM2OD1zNDDuUS=>	NYLJfWNLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwNVIzPDhpPkKzNFEzOjR6PD;hQi=>
H2030	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUDJR\|UxRTF{IH7N	MlPKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyMUKyOFgoRjJ\|MEGyNlQ5RC:jPh?=
H23	NXq3UYh1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3rtO2lEPTB;MUGgcm0>	M4WyOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEGyNlQ5Lz5{M{CxNlI1QDxxYU6=
HOP-62	M{njbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF\6b5VKSzVyPUGxJI5O	MoLoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyMUKyOFgoRjJ\|MEGyNlQ5RC:jPh?=
IA-LM	NVO5cHVGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGHMVnVKSzVyPUGwJI5O	NH\DPYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{CxNlI1QCd-MkOwNVIzPDh:L3G+
H460	M{jHTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRThibl2=	MoTsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyMUKyOFgoRjJ\|MEGyNlQ5RC:jPh?=
H157	MljtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M37SOmlEPTB;NzDuUS=>	NHjaSoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{CxNlI1QCd-MkOwNVIzPDh:L3G+
H1355	NGmxeIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkXTTWM2OD13IH7N	M33LflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEGyNlQ5Lz5{M{CxNlI1QDxxYU6=
VCaP	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2TOWmlEPTB;NzDuUS=>	M4TpWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MUWyNFA1Lz5{M{G1NlAxPDxxYU6=
LNCaP	NF7KRWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3K2VmlEPTB;ODDuUS=>	M4jGSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MUWyNFA1Lz5{M{G1NlAxPDxxYU6=
Ramos-RA1	NFz3fmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWDKNIlnUUN3ME23MlQhdk1?	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyM{e0NUc,OjN\|MEO3OFE9N2F-
Karpas-299	NFzXTWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4n0VGlEPTB;OT62JI5O	NF;6NVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwN\|c1OSd-MkOzNFM4PDF:L3G+
Kasumi-1	M363eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVXlPFlQUUN3ME21Mlghdk1?	M33FNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{CzO\|QyLz5{M{OwN\|c1OTxxYU6=
CCRF-CEM (2)	MkO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\JcY5KSzVyPUeuNkBvVQ>?	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyM{e0NUc,OjN\|MEO3OFE9N2F-
CCRF-CEM (1)	M3n0bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHnBb2tKSzVyPUGyMlUhdk1?	NHzobY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwN\|c1OSd-MkOzNFM4PDF:L3G+
MOLT-4	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWjpXJBIUUN3ME2xNE43KG6P	MmKwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MEO3OFEoRjJ\|M{CzO\|QyRC:jPh?=
RS4;11	MnnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{jpTGlEPTB;MUOuOUBvVQ>?	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyM{e0NUc,OjN\|MEO3OFE9N2F-
COG-LL-317	M4fM[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTRwNDDuUS=>	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyM{e0NUc,OjN\|MEO3OFE9N2F-
NALM-6	MkTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\oUIhKSzVyPUGxMlchdk1?	NVjvflhxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFM4PDFpPkKzN\|A{PzRzPD;hQi=>
CHLA-136	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTJ\|LkKgcm0>	NYfi[\|d7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFM4PDFpPkKzN\|A{PzRzPD;hQi=>
CHLA-90	Moq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NULXS2s6UUN3ME2yNk4{KG6P	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyM{e0NUc,OjN\|MEO3OFE9N2F-
NB-EBc1	NWXLe\|QyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTF4Lkigcm0>	NHHIdZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwN\|c1OSd-MkOzNFM4PDF:L3G+
NB-1643	NIfhdVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4DoN2lEPTB;Nz60JI5O	NGfxcJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwN\|c1OSd-MkOzNFM4PDF:L3G+
SJ-GBM2	MkW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGnzcIVKSzVyPUGyMlkhdk1?	NGTFRmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwN\|c1OSd-MkOzNFM4PDF:L3G+
CHLA-258	M1zESGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnXsTWM2OD14LkSgcm0>	Mmi4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MEO3OFEoRjJ\|M{CzO\|QyRC:jPh?=
CHLA-10	NV;Hc5Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2PUfWlEPTB;NT63JI5O	MoPhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MEO3OFEoRjJ\|M{CzO\|QyRC:jPh?=
CHLA-9	NU\XXnhiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M13UbWlEPTB;ND62JI5O	NWPrV3B2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFM4PDFpPkKzN\|A{PzRzPD;hQi=>
TC-71	NXTzT41GT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\6SmlEPTB;ND61JI5O	MnzQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MEO3OFEoRjJ\|M{CzO\|QyRC:jPh?=
CHLA-266	M2P3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoS3TWM2OD1{Nz6xJI5O	M3LSdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{CzO\|QyLz5{M{OwN\|c1OTxxYU6=
BT-12	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTF2LkOgcm0>	MofpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MEO3OFEoRjJ\|M{CzO\|QyRC:jPh?=
Rh30	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXT5fXNNUUN3ME21MlYhdk1?	NWPk[oVvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFM4PDFpPkKzN\|A{PzRzPD;hQi=>
Rh18	MoDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFjocYVKSzVyPU[uNkBvVQ>?	NXi5XFJsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFM4PDFpPkKzN\|A{PzRzPD;hQi=>
Rh41	MnXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4HvWmlEPTB;MUCuOEBvVQ>?	MlrkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MEO3OFEoRjJ\|M{CzO\|QyRC:jPh?=
RD	NFfNUlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoPRTWM2OD16IH7N	NYS2fFJoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFM4PDFpPkKzN\|A{PzRzPD;hQi=>
K033	NFi1[m9CeG:ydH;zbZMhSXO\|YYm=	NIPVe\|AyODBibl2=	MXe3NkBp		NEGxSnh{cWewaX\pZ4FvfGy7IHnu[JVk\XNiYYDvdJRwe2m\|	NYLodHd5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NVg2OjNpPkKzOFE5PTJ\|PD;hQi=>
M23	MnzIRZBweHSxc3nzJGF{e2G7	NEHIWYYyODBibl2=	MUm3NkBp		MlX6d4lodmmoaXPhcpRtgSCrbnT1Z4V{KGGyb4D0c5Nqew>?	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRzOEWyN{c,OjN2MUi1NlM9N2F-
K029	M2DaUWFxd3C2b4Ppd{BCe3OjeR?=	NGCw[lUyODBibl2=	M4\6eFczKGh?		MWXzbYdvcW[rY3HueIx6KGmwZIXj[ZMh[XCxcITvd4l{	NHrtO4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{SxPFUzOyd-MkO0NVg2OjN:L3G+
K028	NFvEe5JCeG:ydH;zbZMhSXO\|YYm=	MkLUNVAxKG6P	NV7LbWhjPzJiaB?=		NYC0bnd{e2mpbnnmbYNidnSueTDpcoR2[2W\|IHHwc5B1d3Orcx?=	NW\F[VBxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NVg2OjNpPkKzOFE5PTJ\|PD;hQi=>
K008	M1fLbGFxd3C2b4Ppd{BCe3OjeR?=	NGrVclcyODBibl2=	MUS3NkBp		NVzCNYp4e2mpbnnmbYNidnSueTDpcoR2[2W\|IHHwc5B1d3Orcx?=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRzOEWyN{c,OjN2MUi1NlM9N2F-
K033	M2PucmZ2dmO2aX;uJGF{e2G7	M3PXdFI2OCCwTR?=	MnHzNlQhcA>?		MXfpcoR2[2W\|IHGgcY9l\XO2IHnuZ5Jm[XOnIHnuJGcyKHCxcIXsZZRqd25?	M4LoXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEG4OVI{Lz5{M{SxPFUzOzxxYU6=
M23	Ml25SpVv[3Srb36gRZN{[Xl?	MVOyOVAhdk1?	NVOzUVgyOjRiaB?=		MnntbY5lfWOnczDHNUBidmRiR{KvUUBienKnc4S=	MlG0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUi1NlMoRjJ\|NEG4OVI{RC:jPh?=
K029	NYC4ZVVQTnWwY4Tpc44hSXO\|YYm=	MWWyOVAhdk1?	NWPLWZNEOjRiaB?=		Mn7rbY5lfWOnczDHNUBienKnc4S=	M4HvV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEG4OVI{Lz5{M{SxPFUzOzxxYU6=
K028	MWDGeY5kfGmxbjDBd5NigQ>?	NVrMSpNCOjVyIH7N	M1Ptb\|I1KGh?		MYXpcoR2[2W\|IFeyJIFzemW\|dB?=	MmfjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUi1NlMoRjJ\|NEG4OVI{RC:jPh?=
K008	NH3YeYVHfW6ldHnvckBCe3OjeR?=	MXOyOVAhdk1?	NEPYTYQzPCCq		MWHpcoR2[2W\|IFeyJIFzemW\|dB?=	MmPqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUi1NlMoRjJ\|NEG4OVI{RC:jPh?=
K033	Mn3pR4VtdCCYaXHibYxqfHliQYPzZZk>				Mo\6TWM2OD15NT61JI5O	NVnvcm5RRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NVg2OjNpPkKzOFE5PTJ\|PD;hQi=>
M23	M1jHbWNmdGxiVnnhZoltcXS7IFHzd4F6				MVjJR\|UxRTN5LkWgcm0>	MlXrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUi1NlMoRjJ\|NEG4OVI{RC:jPh?=
K029	MXTD[YxtKF[rYXLpcIl1gSCDc4PhfS=>				MorlTWM2OD12NjDuUS=>	NXLKbVZmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NVg2OjNpPkKzOFE5PTJ\|PD;hQi=>
K028	M2f2dmNmdGxiVnnhZoltcXS7IFHzd4F6				MmnqTWM2OD16NDDuUS=>	M1\lUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEG4OVI{Lz5{M{SxPFUzOzxxYU6=
K008	MkC4R4VtdCCYaXHibYxqfHliQYPzZZk>				M1rvcmlEPTB;NkCgcm0>	NH7oNVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{SxPFUzOyd-MkO0NVg2OjN:L3G+
H3122	MnrIR4VtdCCYaXHibYxqfHliQYPzZZk>	NVi1V\|RlOC1zMECwJI5O	NVPYdnhbPzJiaB?=		MWjJR\|UxRTFyIH7N	NGXISmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WzN\|I3PSd-MkO1N\|MzPjV:L3G+
H2228	NE\vZ41E\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NUjhZW5lOC1zMECwJI5O	MWq3NkBp		MXTJR\|UxRTF\|IH7N	NYLoN4RERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1N\|MzPjVpPkKzOVM{OjZ3PD;hQi=>
A1847	NG[3eXlCeG:ydH;zbZMhSXO\|YYm=	NYXsWlNVOTBvMUCwJI5O	NWjrTmZMOjRxNEivO\|IhcA>?		NGr5O3dqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nIHHu[EBld3OnIHTldIVv\GWwdHz5	MniyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MECxN\|YoRjJ\|OUCwNVM3RC:jPh?=
OVCAR-8	NIXifopCeG:ydH;zbZMhSXO\|YYm=	NVvx[FlWOTBvMUCwJI5O	NFLGNpMzPC92OD:3NkBp		NXPFVHF5cW6mdXPld{BieG:ydH;zbZMhfGmvZTDhcoQh\G:\|ZTDk[ZBmdmSnboTsfS=>	NV62bHJ7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5NFAyOzZpPkKzPVAxOTN4PD;hQi=>
OVCAR-5	MYDBdI9xfG:\|aYOgRZN{[Xl?	NWPSSXZxOTBvMUCwJI5O	NGXsfJQzPC92OD:3NkBp		MnH1bY5lfWOnczDhdI9xfG:\|aYOgeIlu\SCjbnSg[I9{\SCmZYDlcoRmdnSueR?=	M1nDN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUCwNVM3Lz5{M{mwNFE{PjxxYU6=
SKOV-3	MlfvR4VtdCCYaXHibYxqfHliQYPzZZk>	M{HPR\|AuOTByMDDuUS=>	M4HmXVczKGh?		M1vhWolvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl?	NUT6VZNYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5NFAyOzZpPkKzPVAxOTN4PD;hQi=>
A1847	NUHNVJdzS2WubDDWbYFjcWyrdImgRZN{[Xl?	NXmxbpVpOC1zMECwJI5O	MV:3NkBp		M2jIfYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl?	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzlyMEGzOkc,OjN7MECxN\|Y9N2F-
OVCAR-8	NGfGe4RE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MVGwMVExODBibl2=	NYD3UWg6PzJiaB?=		NV7HZ5QxcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?=	M3HX[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUCwNVM3Lz5{M{mwNFE{PjxxYU6=
OVCAR-5	MVTD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NX3VbZNrOC1zMECwJI5O	NYPsdVJrPzJiaB?=		MV\pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6	MnHYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MECxN\|YoRjJ\|OUCwNVM3RC:jPh?=
H146	NHfBSIdHfW6ldHnvckBCe3OjeR?=	NHTveoc{OCCwTR?=	MlS5O\|IhcA>?		M2\Obolv\HWlZYOgdIVze2m\|dHXueEBIOi:PIIDoZZNmKGG{cnXzeC=>	NFrWRYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG2OlUxPSd-MkSxOlY2ODV:L3G+
GLC4	NYWxfolOTnWwY4Tpc44hSXO\|YYm=	NEPO[JY{OCCwTR?=	NGLYXYU4OiCq		M4PNOolv\HWlZYOgdIVze2m\|dHXueEBIOi:PIIDoZZNmKGG{cnXzeC=>	MoXVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNk[1NFUoRjJ2MU[2OVA2RC:jPh?=
H82	MYnGeY5kfGmxbjDBd5NigQ>?	NE[xfGg{OCCwTR?=	MnfZO\|IhcA>?		M1PwVYlv\HWlZYOgdIVze2m\|dHXueEBIOi:PIIDoZZNmKGG{cnXzeC=>	NYC0dJVYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOlY2ODVpPkK0NVY3PTB3PD;hQi=>
AC3	Mn:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEP3ZW5KSzVyPUK1Mlkhdk1?	Ml3rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNk[1NFUoRjJ2MU[2OVA2RC:jPh?=
H1173	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXfRXHZFUUN3ME2xNk43OiCwTR?=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF4NkWwOUc,OjRzNk[1NFU9N2F-
H792	NWnVSIFpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlrGTWM2OD12NT6wO{BvVQ>?	NYHTV3RtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOlY2ODVpPkK0NVY3PTB3PD;hQi=>
H620	NFHaWJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\pSllKSzVyPUOyMlY4KG6P	M4PNUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MU[2OVA2Lz5{NEG2OlUxPTxxYU6=
N592	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{HTfmlEPTB;MUSuNVIhdk1?	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF4NkWwOUc,OjRzNk[1NFU9N2F-
H526	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUK5RnlJUUN3ME2yNU43PCCwTR?=	NWO2RpNoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOlY2ODVpPkK0NVY3PTB3PD;hQi=>
H187	Ml\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRTJ2Lkm5JI5O	MojqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNk[1NFUoRjJ2MU[2OVA2RC:jPh?=
H146	MoHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVP6SXE5UUN3ME2yPE42OSCwTR?=	MnfZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNk[1NFUoRjJ2MU[2OVA2RC:jPh?=
H128	NUTocXhiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTZ7LkW1JI5O	MkPHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNk[1NFUoRjJ2MU[2OVA2RC:jPh?=
H69	M{fQSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX;HeWdHUUN3ME24N{4{PiCwTR?=	NH[0NpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG2OlUxPSd-MkSxOlY2ODV:L3G+
GLC4	NFzzO\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4i1WGlEPTB;MkCuOFchdk1?	NXXofIJjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOlY2ODVpPkK0NVY3PTB3PD;hQi=>
H82	M{XEUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXH2T2ZmUUN3ME2zNE4zPyCwTR?=	NUnIbHNIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOlY2ODVpPkK0NVY3PTB3PD;hQi=>
MDA-MB-231	M17xU2Z2dmO2aX;uJGF{e2G7	MXuxNFAhdk1?	M3qz[FI1KGh?		MYXpcohq[mm2czD0bIUhdWmpcnH0c5J6KGGwZDDpcpZie2m4ZTDjZZBi[2m2edMg	NH7kbmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG3N\|U1OSd-MkSxO\|M2PDF:L3G+
BT-20	MkHwSpVv[3Srb36gRZN{[Xl?	MUWxNFAwOjVyIH7N	NUTl[40yOjRiaB?=		Mnj1doV{fWy2ZXSgbY4h[SCmb4PlMYRmeGWwZHXueEBl\XO2YXLpcIl7[XSrb36gc4YhTUeIUjygTWdHNUmULDDNSXQtKGGwZDDDVmFH	NWfQXpdSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxO\|M2PDFpPkK0NVc{PTRzPD;hQi=>
MDA-MB-435	NV:zNXp5TnWwY4Tpc44hSXO\|YYm=	MVWxNFAhdk1?	MV[zNEBucW5?		NE\4WJJqdmirYnn0d{Bi[2O3bYXsZZRqd25ib3[gTGlHNTIQsR?=	MlT6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NEiyOlUoRjJ2MkS4NlY2RC:jPh?=
MDA-MB-231	MnPsSpVv[3Srb36gRZN{[Xl?	MkLqNVAxKG6P	MYmzNEBucW5?		MYLpcohq[mm2czDhZ4N2dXWuYYTpc44hd2ZiSFnGMVHPuQ>?	NEe5b2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK0PFI3PSd-MkSyOFgzPjV:L3G+
HCC2998	NYDobVF[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV7XO\|M{UUN3ME2xNlghdk1?	MnLqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4OEK3OFcoRjJ2NkiyO\|Q4RC:jPh?=
SK-CO-1	NFXpXGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlvuTWM2OD16MTDuUS=>	MkjNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4OEK3OFcoRjJ2NkiyO\|Q4RC:jPh?=
LS-123	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXz0bldsUUN3ME23N{BvVQ>?	MkfYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4OEK3OFcoRjJ2NkiyO\|Q4RC:jPh?=
SNU-C2B	M2PQRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGDGTlRKSzVyPUS1JI5O	MlnyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4OEK3OFcoRjJ2NkiyO\|Q4RC:jPh?=
LS-1034	M4frc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYH3VIUzUUN3ME2zNUBvVQ>?	NFe3N4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[4Nlc1Pyd-MkS2PFI4PDd:L3G+
LoVo	NFvmVJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVfj[JM5UUN3ME2yNkBvVQ>?	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ6Mke0O{c,OjR4OEK3OFc9N2F-
COLO-678	Mk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIfsW3BKSzVyPUKxJI5O	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ6Mke0O{c,OjR4OEK3OFc9N2F-
NCI-H747	M3HZUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYS2d2h[UUN3ME2xO{BvVQ>?	Ml7vQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4OEK3OFcoRjJ2NkiyO\|Q4RC:jPh?=
COLO-205	NFS1RXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTF2IH7N	M1jBOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkiyO\|Q4Lz5{NE[4Nlc1PzxxYU6=
HCT 116	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGnMXWxKSzVyPUG0JI5O	NXnSbGxJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2PFI4PDdpPkK0OlgzPzR5PD;hQi=>
HuTu-80	MkLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnmNHZKSzVyPUGzJI5O	M4HhNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkiyO\|Q4Lz5{NE[4Nlc1PzxxYU6=
HCT-15	Mo\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF7tTm5KSzVyPUigcm0>	MkDyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4OEK3OFcoRjJ2NkiyO\|Q4RC:jPh?=
SW620	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHLqb\|dKSzVyPUigcm0>	NITKe489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[4Nlc1Pyd-MkS2PFI4PDd:L3G+
LS-411 N	M4\GZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFqwZotKSzVyPUWgcm0>	NIfYSpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[4Nlc1Pyd-MkS2PFI4PDd:L3G+
RKO	MkH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXLBTIw4UUN3ME20JI5O	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ6Mke0O{c,OjR4OEK3OFc9N2F-
SW780	NIW0W\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnTjTWM2OD1\|NEWxJI5O	NGHWclg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe4OFg{QSd-MkS3PFQ5Ozl:L3G+
RT4	NF3nVFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MorFTWM2OD1zN{OzJI5O	Mne5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OES4N\|koRjJ2N{i0PFM6RC:jPh?=
TCCSUP	NFG1SVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRTF2MjDuUS=>	MnrzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OES4N\|koRjJ2N{i0PFM6RC:jPh?=
MGH-U3	NITxTGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTV\|IH7N	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd6NEizPUc,OjR5OES4N\|k9N2F-
HT-1197	MmXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4K5RmlEPTB;NUOgcm0>	NXXpd21KRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFQ5OzlpPkK0O\|g1QDN7PD;hQi=>
5637	NYXYUXlRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoeyTWM2OD12NDDuUS=>	NFXsS4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe4OFg{QSd-MkS3PFQ5Ozl:L3G+
35612	M1PHVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm\QTWM2OD1\|ODDuUS=>	NV\HZZZRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFQ5OzlpPkK0O\|g1QDN7PD;hQi=>
KU-19-19	NEi3OZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkTLTWM2OD1\|NjDuUS=>	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd6NEizPUc,OjR5OES4N\|k9N2F-
LB831-BLC	MoTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{jsTWlEPTB;M{Sgcm0>	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd6NEizPUc,OjR5OES4N\|k9N2F-
UM-UC3	Mn\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTN\|IH7N	Ml3VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OES4N\|koRjJ2N{i0PFM6RC:jPh?=
647-V	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIXGfWRKSzVyPUK3JI5O	MnjmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OES4N\|koRjJ2N{i0PFM6RC:jPh?=
HT-1376	M3XFRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXnJR\|UxRTJzIH7N	M2jmTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{i0PFM6Lz5{NEe4OFg{QTxxYU6=
J82	Mm\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWDWeGVDUUN3ME2xPEBvVQ>?	MnjMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OES4N\|koRjJ2N{i0PFM6RC:jPh?=
BFTC	M2\nTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHvOXVNKSzVyPUG3JI5O	NXrJU\|k5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFQ5OzlpPkK0O\|g1QDN7PD;hQi=>
SCaBER	MkG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4njWmlEPTB;MUCgcm0>	M{GzbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{i0PFM6Lz5{NEe4OFg{QTxxYU6=
639-V	MoTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mlz1TWM2OD1zMDDuUS=>	NGjvNoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe4OFg{QSd-MkS3PFQ5Ozl:L3G+
RT112	M3zMZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkC4TWM2OD17IH7N	NIDubI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe4OFg{QSd-MkS3PFQ5Ozl:L3G+
T24	NGjnTGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTdibl2=	NH7xcVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe4OFg{QSd-MkS3PFQ5Ozl:L3G+
SW-1710	NXvSNI1zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWrnclkyUUN3ME22JI5O	NY\vVpp4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFQ5OzlpPkK0O\|g1QDN7PD;hQi=>
DSH1	Mlz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWmzSFh2UUN3ME22JI5O	NWfpNW86RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFQ5OzlpPkK0O\|g1QDN7PD;hQi=>
CAL27	NFzWOZhEgXSxeHnjbZR6KEG\|c3H5	M{S2TlExNzVyIH7N	NXGwdVJ3OjRiaB?=		NFvWXmpl\WO{ZXHz[ZMh[2WubDDwdo9tcW[ncnH0bY9vKGSxc3Wg[IVx\W6mZX70cJk>	NXXaPYI6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNFU1OzBpPkK1NlA2PDNyPD;hQi=>
Detroit562	MlfGR5l1d3irY3n0fUBCe3OjeR?=	NWn3UYdCOTBxNUCgcm0>	NWfWXpY1OjRiaB?=		Mnex[IVkemWjc3XzJINmdGxicILvcIln\XKjdHnvckBld3OnIHTldIVv\GWwdHz5	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJyNUSzNEc,OjV{MEW0N\|A9N2F-
FUDA	M2nGPWN6fG:6aXPpeJkhSXO\|YYm=	NIj3flYyOC93MDDuUS=>	MUSyOEBp		M{W1UoRm[3KnYYPld{Bk\WyuIIDyc4xq\mW{YYTpc44h\G:\|ZTDk[ZBmdmSnboTsfS=>	NGXKV4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKwOVQ{OCd-MkWyNFU1OzB:L3G+
SCC25	NFfWclNEgXSxeHnjbZR6KEG\|c3H5	M{GwZVExNzVyIH7N	NYG2fVByOjRiaB?=		Ml7Y[IVkemWjc3XzJINmdGxicILvcIln\XKjdHnvckBld3OnIHTldIVv\GWwdHz5	NEXGfJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKwOVQ{OCd-MkWyNFU1OzB:L3G+
HT-29	NV\kTlhWTnWwY4Tpc44hSXO\|YYm=	MWe1NI5O	NX:5b5pYOjRiaB?=	MmO3SG1UVw>?	NVjU[JN[cW6mdXPl[EBIOC:JMTDhdpJme3R?	Mnu3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MUC3PVQoRjJ3MkGwO\|k1RC:jPh?=
HCT-116	MWTGeY5kfGmxbjDBd5NigQ>?	NGjVb3o2OG6P	NFj5T3AzPCCq	NHzWPI5FVVOR	NHzxcm5qdmS3Y3XkJGcxN0dzIHHydoV{fA>?	NXvmOYo4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNVA4QTRpPkK1NlExPzl2PD;hQi=>
MGC-803	NYr5R5FLTnWwY4Tpc44hSXO\|YYm=	M4fwOlAvOS1zMECwJI5O	NILUUY4zPCCq		NYqycox1cW6mdXPld{BIOi:PIHPlcIwu[3mlbHWgZZJz\XO2	MoL5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3OUC4NFUoRjJ3NUmwPFA2RC:jPh?=
MKN-28	NFz5SmlE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NXX4T29QOC5zLUGwNFAhdk1?	NVq5d4h1PzJiaB?=		MVfpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6	MmfIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3OUC4NFUoRjJ3NUmwPFA2RC:jPh?=
SGC-7901	Ml\4R4VtdCCYaXHibYxqfHliQYPzZZk>	Mof4NE4yNTFyMECgcm0>	M{Dl[lczKGh?		MnjDbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>?	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV7MEiwOUc,OjV3OUC4NFU9N2F-
MGC-803	MW\D[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MUWwMlEuOTByMDDuUS=>	NVL0S\|dZPzJiaB?=		NIPFN3JqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7	M2K3blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUmwPFA2Lz5{NUW5NFgxPTxxYU6=
MV411	NVS2eWo3SXCxcITvd4l{KEG\|c3H5	MmjGN\|AwQDBxMUWwM\|I2OCCwTR?=	NWmxW4Q3OjRxNEivO\|IhcA>?		NHmzdplqdmS3Y3XzJIRwe2ViZHXw[Y5l[W62IHnu[JVkfGmxbjDv[kBieG:ydH;zbZM>	MlzBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6OEK1OVAoRjJ3OEiyOVUxRC:jPh?=
HL60	M4myeWFxd3C2b4Ppd{BCe3OjeR?=	NXOwV3c6OzBxOECvNVUxNzJ3MDDuUS=>	MUGyOE81QC95MjDo		M{nGbYlv\HWlZYOg[I9{\SCmZYDlcoRidnRiaX7keYN1cW:wIH;mJIFxd3C2b4Ppdy=>	NFjOZYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi4NlU2OCd-MkW4PFI2PTB:L3G+
TC32	NX:2c2hEeUiWUzDhd5NigQ>?				M1L6bJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCWQ{OyJINmdGy\|	M4\1T\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673	M{XDT5FJXFNiYYPzZZk>				MkHPdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN?	MoK4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Saos-2	MXLxTHRUKGG\|c3H5				NETiS5ZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz	M3nYNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37	M{jNTpFJXFNiYYPzZZk>				MmXGdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUO3JINmdGy\|	M3zFO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD	MUfxTHRUKGG\|c3H5				NV;BToVIeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLEJINmdGy\|	M4rwWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH	NVzEXIFHeUiWUzDhd5NigQ>?				NYnFdm9SeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uW0hiY3XscJM>	Ml3nQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB1643	MULxTHRUKGG\|c3H5				MUnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy\|	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
OHS-50	MUDxTHRUKGG\|c3H5				MXjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy\|	M4jaWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673	NHPEOWpyUFSVIHHzd4F6				MmPTdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgRVY4OyClZXzsd{k>	M2j5XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2	MkHQdWhVWyCjc4PhfS=>				MYXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?=	M4fBO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC	NEXIdGNyUFSVIHHzd4F6				MkTVdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB-EBc1	MX3xTHRUKGG\|c3H5				MonJdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ\|Eh[2WubIO=	NGOx[IE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
LAN-5	Ml3tdWhVWyCjc4PhfS=>				MYPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN?	MnXJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh18	M3PFUJFJXFNiYYPzZZk>				MlzPdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqMUigZ4VtdHN?	MljWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	EGFR / c-Met / IGF-1Rβ/ Akt / p-Akt / ERK / p-ERK; PubMed: 23418523 PLoS One Downregulation of multiple signaling pathways by ganetespib in melanoma cells.A. Cells were treated with indicated amounts of ganetespib for 24 h. B-RAF and N-RAS mutational status of each cell line is indicated. p27(Kip1) / p21 (Cip1) / Cyclin D1 / Cyclin E / Cyclin B1 / CDK1 / CDK2 / CDK4; PubMed: 23418523 PLoS One Alterations in expression of multiple cell cycle regulating proteins induced by ganetespib. Cells were treated with indicated amounts of ganetespib for 48 h and analyzed by Western blot analysis. Relative expression levels of proteins (treated vs. control䲧疝Ỵ疞㧀疜膉痘  Survivin / Bcl-2 / Bcl-xl / Mcl-1; PubMed: 23418523 PLoS One Effect of ganetespib on the expression of antiapoptotic proteins. Cells were treated with ganetespib for 48 h and analyzed using Western blot analysis. Relative expression levels of proteins are indicated. B-RAF / C-RAF / N-RAS ; PubMed: 23418523 PLoS One Effect of ganetespib on B-RAF, C-RAF and N-RAS expression in melanoma cells.Cells were treated with indicated amounts of ganetespib for 48 h and subjected to Western blot analysis. HER2 / p-STAT3 / BIM ; PubMed: 25077897 Target Oncol NCI-H1975 cells were incubated with the indicated concentrations of ganetespib for 24 h. Cell lysates were analyzed by Western blotting. CDK1 / Cyclin D1 / Cyclin B1 / p27; PubMed: 29717218 Sci Rep Cropped Western blot images of the indicated cell cycle regulators are shown in ganetespib-treated (0–300 nM for 16 hours) BT474 and SKBR3 cells. c-PARP / c-caspase 3 / caspase 8 / c-caspase 8 / caspase 9 / c-caspase 9; PubMed: 29717218 Sci Rep Cropped images of Western blots at the target molecular weights for the indicated apoptotic markers are shown in ganetespib-treated (0, 10, 30, 100, 300 nM for 16 hours) BT474 and SKBR3 cells. ErbB2 / pErbB2 / Src / pSrc / mTOR / pmTOR / Bad / pBad / GSK3 / pGSK3; PubMed: 29717218 Sci Rep Ganetespib inhibits RTK signaling in ErbB2+ breast cancer cells. BT474 and SKBR3 cells were treated with ganetespib (0, 10, 30, 100, or 300 nM) for 16 hours, followed by Western blot analysis (cropped images) of the expression and activation/phosphorylati䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖 Wee1 / p-Wee1 / Chk1 / p-Chk1; PubMed: 27834954 Cell Death Differ Hsp90 inhibition degrades the G2/M checkpoint kinases Wee1 and Chk1. The cells were treated with 200 nM ganetespib and 75 μM carboplatin for 24 h followed by immunoblot analysis. Carboplatin treatment leads to the activation of Chk1, indicated by phospho—䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ	23418523 25077897 29717218 27834954
Growth inhibition assay	Cell viability ; PubMed: 23418523 PLoS One A. Ganetespib reduced viability. Cells were treated with varying amounts of ganetespib for 72 h and subjected to MTS assay. Data are expressed as mean±SD of three independent experiments. B. Mutational status and ganetespib IC50 of cell lines.	23418523

In vivo

Administration of Ganetespib leads to significant tumor shrinkage in several tumor xenograft models in mice and appears to be less toxic. Furthermore Ganetespib demonstrated better tumor penetration compared with tanespimycin.^[2] Ganetespib inhibits in vivo tumor growth in both malignant mast cell and OSA xenograft models. Ganetespib significantly inhibits tumor growth when dosed with two repeating cycles of 25 mg/kg/day for 3 days, with a %T/C value of 18. Ganetespib is well-tolerated, with the vehicle and Ganetespib groups having average bodyweight changes relative to the start of the study of +0.3% and -8.1% on day 17, respectively.^[4]

Protocol

Cell Research:^[1]

- Collapse

Cell lines: OSA cells
Concentrations: 0.001-1μM
Incubation Time: 5 days
Method: A total of 1.5 × 10³ OSA cells are seeded in 96-well plates in 10% serum-containing complete medium and incubated overnight to determine the 50% inhibitory concentrations. Plates are, harvested at day 5 following 0.001, 0.005, 0.01, 0.05, 0.1, 0.5 and 1 μM Ganetespib, treatment and analyzed. Fluorescence measurements are made using a plate reader with excitation at 485 nm and emission detection at 530 nm. Relative cell number is calculated as a percentage of the control wells: absorbance of sample/absorbance of DMSO treated cells × 100.
(Only for Reference)

Animal Research:^[4]

- Collapse

Animal Models: Female severe combined immune-deficient (SCID) mice
Dosages: 25 mg/kg/day for 3 days
Administration: Tail vein injection
(Only for Reference)

References

[4] Lin TY, et al. Exp Hematol. 2008, 36(10), 1266-1277.

- Collapse

Solubility (25°C)

In vitro	DMSO	40 mg/mL (109.76 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+45% PEG 300+ddH2O For best results, use promptly after mixing.	11mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Ganetespib (STA-9090) SDF

Molecular Weight	364.4
Formula	C₂₀H₂₀N₄O₃
CAS No.	888216-25-9
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC(C)C1=C(C=C(C(=C1)C2=NNC(=O)N2C3=CC4=C(C=C3)N(C=C4)C)O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02192541	Terminated	Drug: Ziv-Aflibercept\|Drug: Ganetespib	Neoplasms	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	December 2 2014	Phase 1
NCT02008877	Completed	Drug: ganetespib\|Drug: Sirolimus	Malignant Peripheral Nerve Sheath Tumors (MPNST)\|Sarcoma	Sarcoma Alliance for Research through Collaboration\|Synta Pharmaceuticals Corp.\|United States Department of Defense	December 2013	Phase 1\|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Does this inhibitor inhibit both isoforms of HSP90?
Answer:
We don't have the information now and it is not very clear in the literature either. From following two references, it indicates that Ganetespib might be specific to the alpha form “Ganetespib binds to the ATP binding site of Hsp90 alpha with a Kd of 110 nM” http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477583/

HSP (HSP90) Signaling Pathway Map

HSP (HSP90) Inhibitors with Unique Features

Selective HSP90 Inhibitor

NVP-BEP800 : HSP90β-selective, IC50=58 nM.
Most Potent HSP90 Inhibitor

KW-2478 : HSP90, IC50=3.8 nM.
HSP90 Inhibitor in Clinical Trial

17-AAG (Tanespimycin) : Phase III for Gastrointestinal Stromal Tumors.
Newest HSP90 Inhibitor

XL888 : ATP-competitive inhibitor of HSP90 with IC50 of 24 nM.

Related HSP (HSP90) Products

PU-H71 ^New

PU-H71 (NSC 750424) is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. Phase 1.
KNK437 ^New

KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40.
VER155008 ^New

VER155008 (C07) is a potent Hsp70 family inhibitor with IC50 of 0.5 μM, 2.6 μM, and 2.6 μM in cell-free assays for HSP70, HSC70, and GRP78 (HSPA5, Bip), respectively, >100-fold selectivity over HSP90. VER155008 inhibits autophagy and causes reduced levels of HSP90 client proteins.
Tanespimycin (17-AAG)

Tanespimycin (17-AAG, CP127374, NSC-330507, KOS 953) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Tanespimycin (17-AAG) induces apoptosis, necrosis, autophagy and mitophagy. Phase 3.

Features:Displays very low toxicity toward normal cells.
Luminespib (NVP-AUY922)

Luminespib (AUY-922, NVP-AUY922, VER-52296) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Luminespib (AUY-922, NVP-AUY922) effectively downregulates and destabilizes the IGF-1Rβ protein and results in growth inhibition, autophagy and apoptosis. Phase 2.
Alvespimycin (17-DMAG) HCl

Alvespimycin (17-DMAG, NSC 707545, BMS 826476, KOS 1022) HCl is a potent HSP90 inhibitor with IC50 of 62 nM in a cell-free assay. Phase 2.

Features:A synthetic derivative Geldanamycin, with lower hepatotoxicity than parent antibiotic & higher potency and bioavailability than the similar derivative 17-AAG.
Geldanamycin (NSC 122750)

Geldanamycin (NSC 122750) is a natural existing HSP90 inhibitor with K_d of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association. Geldanamycin attenuates virus infection-induced ALI (acute lung injury)/ARDS (acute respiratory distress syndrome) by reducing the host's inflammatory responses.
HSP990 (NVP-HSP990)

HSP990 (NVP-HSP990) is a novel, potent and selective HSP90 inhibitor for HSP90α/β with IC50 of 0.6 nM/0.8 nM. NVP-HSP990 induces cell cycle arrest and apoptosis.

Features:NVP-HSP990 is an orally available HSP90 inhibitor and is structurally distinct from other clinical HSP90 inhibitors.
Elesclomol (STA-4783)

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
Onalespib (AT13387)

Onalespib (AT13387) is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Ganetespib (STA-9090)